Literature DB >> 10692526

Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients.

M Morena1, J P Cristol, T Dantoine, M A Carbonneau, B Descomps, B Canaud.   

Abstract

INTRODUCTION: Cardiovascular diseases represent the major cause of mortality in haemodialysis (HD) patients. Oxidized low-density lipoprotein (Ox-LDL) is a major cardiovascular risk factor, implicated in atherosclerotic plaque formation. It has been suggested that high-density lipoprotein (HD) has the capacity to reduce the oxidative modifications of LDL. The aim of this study is to analyse the protective effects of HDL in HD patients.
METHODS: In vitro copper-induced LDL oxidation was evaluated in 12 patients with chronic renal failure (mean age 61.0+/-12.8 years) and compared to 25 healthy subjects (mean age 57.3+/-19.2 years). LDL were incubated in oxygen-saturated PBS, LDL oxidation was initiated by Cu (II) in the presence and absence of HDL and assessed by measuring the absorbance (abs) increase at 234 nm due to conjugated diene formation. Duration of lag time, maximum velocity (V(max.)) of lipid peroxidation, oxidation slope and half-time of maximum diene formation (T (1/2)) were obtained by kinetic modelling analysis.
RESULTS: HDL (1.06+/-0.31 vs 1.23+/-0.39 mmol/l) and Apo AI (1. 17+/-0.39 vs 1.49+/-0.20 g/l) levels were decreased in HD patients. In the absence of HDL, LDL obtained from HD patients showed an enhanced susceptibility to oxidation in vitro as demonstrated by the significant decrease in lag time (54.5+/-22.2 vs 79.4+/-37.8 min) and a significant increase in V(max.) (0.026+/-0.006 vs 0.017+/-0. 005 abs/min). In all cases, HDL (from 0.1 to 2 microM) prevented LDL oxidation in vitro; however, this effect was significantly reduced in HD patients: increase in lag time 54.2% vs 150.4% in HD vs controls; increase in T (1/2) 52.2% vs 124.6% in HD vs controls; decrease in V(max). 13.5% vs 38.5% in HD vs controls.
CONCLUSIONS: These results suggest that qualitative abnormalities such as an impairment of HDL-associated enzymes are associated with a decrease of HDL levels during HD. Hence, in addition to the known impairment of reverse cholesterol transport, the reduction of HDL protective capacity against oxidative stress could be involved in the development of HD-induced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692526     DOI: 10.1093/ndt/15.3.389

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

Review 3.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

4.  Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Hiroki Suzuki; Nozomu Hosaka; Yuki Hirai; Mari Nakamura; Hisako Nagai; Noriyuki Kato; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-15       Impact factor: 8.237

Review 5.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

6.  IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.

Authors:  Adriana M Hung; Yohei Tsuchida; Kristen L Nowak; Sudipa Sarkar; Michel Chonchol; Victoria Whitfield; Natjalie Salas; Anna Dikalova; Patricia G Yancey; Jiansheng Huang; MacRae F Linton; T Alp Ikizler; Valentina Kon
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-23       Impact factor: 8.237

Review 7.  Modifying the anti-inflammatory effects of high-density lipoprotein.

Authors:  Benjamin J Ansell; Gregg C Fonarow; Mohamad Navab; Alan M Fogelman
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

8.  HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach.

Authors:  Alain Mangé; Aurélie Goux; Stéphanie Badiou; Laure Patrier; Bernard Canaud; Thierry Maudelonde; Jean-Paul Cristol; Jérôme Solassol
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  A remarkable age-related increase in SIRT1 protein expression against oxidative stress in elderly: SIRT1 gene variants and longevity in human.

Authors:  Ulkan Kilic; Ozlem Gok; Ufuk Erenberk; Mehmet Rusen Dundaroz; Emel Torun; Yasar Kucukardali; Birsen Elibol-Can; Omer Uysal; Tolga Dundar
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 10.  Role of Myeloperoxidase in Patients with Chronic Kidney Disease.

Authors:  Bojana Kisic; Dijana Miric; Ilija Dragojevic; Julijana Rasic; Ljiljana Popovic
Journal:  Oxid Med Cell Longev       Date:  2016-04-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.